Table 4.
Therapeutic strategy among the three groups.
| Groups | MuSK-MG | AChR-MG | DSN-MG |
|---|---|---|---|
| Pyridostigmine bromide | 8/14 (57.1%) | 130/130 (100%) | 39/39 (100%) |
| Glucocorticoid | 14/14 (100%) | 94/130 (72.3%) | 16/39 (33.3%) |
| Immunosuppressant | 13/14 (92.9%) | 86/130 (66.2%) | 1/39 (2.6%) |
| Intravenous immunoglobulin | 6/14 (42.9%) | 37/130 (28.5%) | 5/39 (12.8%) |
| Plasma exchange | – | 2/130 (1.6%) | – |